CJC/Ipamorelin
The CJC-1295 / Ipamorelin blend is the most widely researched peptide combination for stimulating natural growth hormone release. It pairs CJC-1295 (No DAC), a GHRH analog, with Ipamorelin, a selective ghrelin receptor agonist (GHRP). Together, these two peptides act on different but complementary pathways in the pituitary, producing a stronger, cleaner GH pulse than either compound alone. Pre-mixed in a single vial for convenience, this blend has become the gold standard for GH-focused research protocols due to its synergistic effects, favorable side-effect profile, and ease of administration.
The two peptides in this blend work through separate but synergistic mechanisms. CJC-1295 binds to GHRH receptors in the anterior pituitary, stimulating the synthesis and pulsatile release of growth hormone while preserving natural feedback rhythms. Ipamorelin binds to ghrelin receptors (GHSR-1a) on pituitary somatotrophs, triggering GH release through a separate pathway and simultaneously suppressing somatostatin, the hormone that inhibits GH release. The result is a multiplied GH pulse: CJC-1295 increases the amplitude of each pulse, Ipamorelin removes the brake, and the combined effect produces significantly higher GH release than either peptide alone. Importantly, Ipamorelin is highly selective for GH and does not meaningfully elevate cortisol, prolactin, or aldosterone — a key advantage over older GHRPs like GHRP-6 or Hexarelin.
- Synergistic GH release through dual-pathway stimulation
- Preserves natural pulsatile GH rhythm and feedback loops
- Highly selective for GH without elevating cortisol or prolactin
- Supports lean muscle development and tissue repair
- Enhances fat metabolism and body composition
- Significantly improves sleep quality and depth
- Supports skin elasticity and anti-aging research
- Increases IGF-1 levels through endogenous GH release
- Convenient single-vial administration
- Favorable side-effect profile compared to other GHRP combinations
- Injection site redness, swelling, or irritation
- Mild flushing or warmth following administration
- Possible head rush or lightheadedness shortly after injection
- Transient water retention or tingling in extremities
- Mild hunger increase from ghrelin receptor activation
- Vivid dreams or altered sleep architecture
- Possible lethargy on waking after pre-bed dosing
- Not approved for human use; sold strictly for research purposes
- Long-term safety profile in humans has not been fully established
- Consult a qualified medical professional before any use
Considered the gold standard GHRH/GHRP combination in peptide research Pairs with PEG-MGF or IGF-1 LR3 for amplified muscle growth protocols Complements BPC-157 and TB-500 in recovery and tissue repair stacks Stacks with Tesamorelin for advanced GH research protocols Often combined with Kisspeptin-10 for full endocrine axis support Best researched on an empty stomach to avoid GH blunting from elevated insulin Optimal dosing windows: post-workout, pre-bed, and upon waking Pre-bed dose particularly valued for sleep quality and overnight GH pulse Typical research dosing: 200-300 mcg total blend, 1-2x daily Reconstitute with bacteriostatic water; refrigerate after mixing Use within 2-3 weeks of reconstitution for peptide stability
Select your preferred supplier and add to cart. Prices shown include VAT.
| Supplier / Lab | Strength / Volume | Price | Availability | |
|---|---|---|---|---|
|
VM
VMed
South Africa
|
18mg
1 Vial
|
R925
|
In Stock |